• Parkinsonism of arteriosclerotic, idiopathic & post-encephalitic origin, •Control of neuroleptic drug-induced extrapyramidal symptoms, such as pseudoparkinsonism, akathisia & acute dystonic reactions.
Antimuscarinic; Antiparkinson agent
Procyclidine hydrochloride is an antimuscarinic antiparkinsonian agent of relatively low toxicity. It is a synthetic tertiary amine. This drug exerts their antiparkinsonian effect by correcting the relative cholinergic excess which is thought to occur in parkinsonian as a result of dopamine deficiency. It is absorbed from G.I. tract and disappears rapidly from the tissues. After intravenous administration, it acts within 5 to 20 minutes and has a duration of effect up to 4 hours.
2.5 mg 3 times a day, then 5 mg 3 times a day & occasionally 5 mg at night.
The anticholinergic activity of procyclidine may be increased by agents having anticholinergic amantadine. The absorption of ketoconazole may be reduced by concomitant administration of procyclidine.
Caution in children & geriatric patients. It is advisable to be cautious in giving Perkinil to patients with diarrhea & cardiovascular disease, glaucoma, urinary retention, hepatic or renal impairment.
Dryness of the mouth , Mydriasis, blurred vision & adverse G.I. effects (nausea, vomiting, epigastric distress, constipation), an allergic reaction (rash) or muscular weakness, vertigo, confusion & hallucination.
If anticholinergic effects are seen, the dose of procyclidine should be reduced. The safety of using procyclidine during pregnancy has not been established. However, extensive clinical use has not given any evidence that it in any way compromises the normal course of pregnancy. No information is available on the passage of procyclidine into human breast milk following administration of Procyclidine.
Protect from light and moisture, store below 25°C. Keep out of the reach of children.
.png&w=384&q=75)